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OBJECTIVE—The induction of obesity, dyslipidemia, and insu-
lin resistance by high-fat diet in rodents can be prevented by n-3
long-chain polyunsaturated fatty acids (LC-PUFAs). We tested a
hypothesis whether AMP-activated protein kinase (AMPK) has a
role in the beneﬁcial effects of n-3 LC-PUFAs.
RESEARCH DESIGN AND METHODS—Mice with a whole-
body deletion of the 2 catalytic subunit of AMPK (AMPK2
/)
and their wild-type littermates were fed on either a low-fat chow,
or a corn oil-based high-fat diet (cHF), or a cHF diet with 15%
lipids replaced by n-3 LC-PUFA concentrate (cHFF).
RESULTS—Feeding a cHF diet induced obesity, dyslipidemia,
hepatic steatosis, and whole-body insulin resistance in mice of
both genotypes. Although cHFF feeding increased hepatic
AMPK2 activity, the body weight gain, dyslipidemia, and the
accumulation of hepatic triglycerides were prevented by the
cHFF diet to a similar degree in both AMPK2
/ and wild-
type mice in ad libitum-fed state. However, preservation of
hepatic insulin sensitivity by n-3 LC-PUFAs required functional
AMPK2 and correlated with the induction of adiponectin and
reduction in liver diacylglycerol content. Under hyperinsuline-
mic-euglycemic conditions, AMPK2 was essential for preserv-
ing low levels of both hepatic and plasma triglycerides, as well as
plasma free fatty acids, in response to the n-3 LC-PUFA
treatment.
CONCLUSIONS—Our results show that n-3 LC-PUFAs prevent
hepatic insulin resistance in an AMPK2-dependent manner and
support the role of adiponectin and hepatic diacylglycerols in the
regulation of insulin sensitivity. AMPK2 is also essential for
hypolipidemic and antisteatotic effects of n-3 LC-PUFA under
insulin-stimulated conditions. Diabetes 59:2737–2746, 2010
N
aturally occurring n-3 long-chain polyunsatu-
rated fatty acids (LC-PUFAs)—namely, eicosa-
pentaenoic acid (20:5n-3) and docosahexaenoic
acid (22:6n-3)—which are abundant in sea ﬁsh,
act as hypolipidemics, reduce cardiac events, and de-
crease the progression of atherosclerosis [reviewed in refs
(1,2).]. Studies of obese humans have also demonstrated a
reduction in adiposity after n-3 LC-PUFA supplementation
(3,4). In rodents fed a high-fat diet, n-3 LC-PUFAs efﬁ-
ciently prevented the development of obesity, hepatic
steatosis, and dyslipidemia (5–8), as well as impaired
glucose tolerance (8–10). However, in diabetic patients,
n-3 LC-PUFAs appear to have little effect on glycemic
control (3,11,12).
The hypolipidemic and antiobesity effects of n-3 LC-
PUFAs depend on both the suppression of lipogenesis and
the increase in fatty acid oxidation in several tissues,
including the liver (13,14), adipose tissue (6), and intestine
(15). This metabolic switch may reduce the accumulation
of toxic fatty acid derivatives, while protecting insulin
signaling in the liver and muscle (9,10,16). Our previous
work has documented that the preservation of whole-body
insulin sensitivity by n-3 LC-PUFAs in mice fed a high-fat
diet mainly reﬂects improved hepatic insulin sensitivity
(8). The effects of n-3 LC-PUFAs and their active metabo-
lites (17,18) are mediated by peroxisome proliferator-
activated receptors (PPAR), with PPAR- and PPAR- (-)
being the main targets (14,16), although PPAR-, liver X
receptor-, hepatic nuclear factor-4, sterol regulatory ele-
ment binding protein-1c (SREBP-1c) and carbohydrate-
responsive element-binding protein are also involved
(16,19–21).
It has been demonstrated that n-3 LC-PUFAs enhanced
AMP-activated protein kinase (AMPK) activity in the liver
(22), intestine (23), and adipose tissue (18,24). AMPK is a
heterotrimeric protein consisting of a catalytic -subunit
and regulatory - and -subunits, with multiple isoforms
identiﬁed for each subunit [1, 2, 1, 2, 1, 2, and 3;
reviewed in ref (25)]. Experiments using whole-body
AMPK2 null [AMPK2
/; ref (26)] mice showed the
importance of the AMPK2 subunit for whole-body insulin
action, while liver-speciﬁc AMPK2 knockout mice (27) as
well as adenovirus-mediated activation of AMPK2i nt h e
liver (28) implicated the hepatic AMPK2 isoform in the
suppression of hepatic glucose production and mainte-
nance of fasting blood glucose levels. Furthermore, AMPK
controls metabolic ﬂuxes in response to changing cellular
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dation and lipogenesis (29,30).
We hypothesized that the effects of n-3 LC-PUFA on
insulin sensitivity and lipid metabolism in mice fed an
obesogenic high-fat diet require a functional AMPK2
isoform. To test this hypothesis in vivo, AMPK2
/ and
wild-type mice were fed either a low-fat chow diet (Chow),
a corn oil-based high-fat (cHF) diet, or cHF diet in which
15% of the lipids were replaced by n-3 LC-PUFA concen-
trate (cHFF). Our results demonstrate an AMPK2-
dependent action of n-3 LC-PUFAs, in 1) the preservation
of hepatic and muscle insulin sensitivity; 2) the changes in
hepatic diacylglycerol content and composition; and 3) the
antisteatotic effect in the liver and hypolipidemic effect
under insulin-stimulated conditions, such as during hyper-
insulinemic-euglycemic clamp, but not when the organism
depends on lipids as substrates.
RESEARCH DESIGN AND METHODS
Four-month-old whole-body AMPK2
/ mice (29) backcrossed to C57BL/6J
mice for nine generations, and wild-type littermate controls were fed on either
Chow, cHF, or cHFF diet for nine weeks. Body weight and food consump-
tion were recorded, and EDTA-plasma and tissues were collected for various
analyses as described in the online appendix, available at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-1716/DC1. Male mice were used for
all the experiments, except for the measurements of hepatic AMPK activity,
which were performed on female mice. The experiments were conducted
under the guidelines for the use and care of laboratory animals of the Institute
of Physiology and followed the “Principles of laboratory animal care” (Na-
tional Institutes of Health publication no. 85-23, revised 1985).
Blood and plasma parameters. Blood glucose was measured using cali-
brated glucometers (LifeScan, Milpitas, CA). Nonesteriﬁed fatty acids (NE-
FAs), triglycerides, and total cholesterol were determined in plasma using the
following enzymatic photometric tests: NEFA-C (Wako Chemicals, Neuss,
Germany), triacylglycerols liquid, and cholesterol liquid (Pliva-Lachema Diag-
nostika, Brno, Czech Republic), respectively. Plasma insulin was measured
using the Sensitive Rat Insulin RIA Kit (LINCO Research, St. Charles, MO).
Total adiponectin levels and adiponectin multimeric complexes were deter-
mined using Western blotting (31).
Lipid content and gene expression in the liver. The tissue content of
triglycerides was estimated in ethanolic KOH tissue lysates as described
before (8). The content and fatty acid composition of the phospholipid,
diacylglycerol, triglyceride, and ceramide fractions were assessed in tissue
lipid extracts; gene expression was evaluated using real-time RT-PCR (see
online appendix).
Activity of 1 and 2 AMPK isoforms. Livers were collected by freeze-
clamping, AMPK was immunoprecipitated from tissue extracts, and the
activity was assayed using a peptide substrate (32); see the online appendix.
Hyperinsulinemic-euglycemic clamp. Five days before the experiment, an
indwelling catheter was placed into the left femoral vein under anesthesia
(33). Mice were allowed to recover for 5–7 days, followed by a 6-h fast (8:00
A.M.–2:00 P.M.) prior to the experiment. The whole-body glucose turnover was
determined under basal (nonstimulated) and insulin-stimulated conditions
(hyperinsulinemic-euglycemic clamp), using separate groups of mice. Insulin
(Actrapid, Novo Nordisk Pharma, Denmark) was infused at a constant rate of
4.8 mU/kgmin for 3 h, while D-[3-
3H]glucose (Perkin Elmer, Boston, MA) was
infused at a rate of 15.9 kBq/min. Throughout the infusion, glucose concen-
tration and D-[3-
3H]glucose speciﬁc activity (during the last hour of infusion)
were determined in tail blood. Euglycemia (5.55 mmol/l) was maintained by
periodically adjusting a variable infusion of 33% glucose (33). At the end of a
3-h infusion period, mice were ﬁrst anesthetized by diethylether, exsangui-
nated through the cervical incision, and then killed by cervical dislocation,
and tissues (liver and quadriceps muscle) and EDTA-plasma were collected
for biochemical analyses (see supplementary Table 1 and Research Design
and Methods of the online appendix for details on basic clamp parameters and
methodology).
Primary cultures of hepatocytes. Hepatocytes were isolated from livers of
fed mice by a modiﬁcation of the collagenase method (34) and seeded at a
density of 0.5  10
6 cells per each 35-mm Petri dish. Rates of basal and
insulin-stimulated de novo lipogenesis and AICAR-stimulated fatty acid oxi-
dation were measured using [1-
14C] acetate and [1-
14C] palmitate, respectively
(see online appendix).
Statistics. All values are presented as means 	 SE. Data were analyzed by
two-way ANOVA. Comparisons were judged to be signiﬁcant at P  0.05.
RESULTS
Enhancement of hepatic AMPK2 activity by n-3
LC-PUFAs. Speciﬁc activities of AMPK1 and AMPK2
were evaluated in the liver of ad libitum-fed mice after
nine weeks of the differential dietary treatment (Fig. 1). No
signiﬁcant effect of either diet (Chow, cHF, and cHFF) or
genotype (wild-type versus AMPK2
/)o nA M P K 1-
speciﬁc activity was observed, although the AMPK1
activity tended to be higher in the AMPK2
/ mice (Fig.
1A). In contrast, AMPK2 activity was stimulated by n-3
LC-PUFAs (cHFF diet; Fig. 1B). AMPK2 activity was
not detected in the AMPK2
/ mice (Fig. 1B). No
changes were detected in the activity of AMPK1 and
AMPK2 in the quadriceps muscle in response to n-3
LC-PUFAs (not shown).
AMPK2 is not required for antiobesity and hypolipi-
demic effects of n-3 LC-PUFAs in ad libitum-fed mice.
At four months of age, at the beginning of dietary treat-
ments, wild-type and AMPK2
/ mice fed the Chow diet
exhibited similar body weights (Table 1). In mice of both
genotypes, cHF-feeding for nine weeks resulted in greater
body weight gain compared with the Chow-fed mice.
However, this effect was less pronounced in AMPK2
/
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FIG. 1. Liver AMPK1( A) and AMPK2( B) activity in wild-type and
AMPK2
/ mice fed either a Chow diet, cHF, or cHFF for 9 weeks.
The data are the means  SE (n  5–8). In the AMPK2
/ mice,
AMPK2 activity was below the detection limit. *P < 0.05 versus
genotype Chow; †P < 0.05 versus genotype cHF.
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/ mice,
the cHFF diet induced smaller body weight gain than the
cHF diet (Table 1 and supplementary Figure 1). None of
the differences in body weight gain could be explained by
caloric intake, which was similar in all experimental
groups (Table 1). The weight of fat depots increased in
response to cHF feeding, while the cHFF diet partially
prevented this increase (Table 1). Triglycerides and NEFA
levels in plasma of ad libitum-fed mice were similar in the
Chow- and cHF-fed mice, while cholesterol levels were
markedly and signiﬁcantly elevated by the cHF diet. n-3
LC-PUFAs lowered plasma lipid levels independently of
AMPK2. Triglycerides and NEFA levels were strongly
reduced, even below the levels observed in the Chow-fed
mice (Table 1).
AMPK2 is essential for the preservation of insulin
sensitivity in response to n-3 LC-PUFAs. After nine
weeks of dietary treatment, no change was observed in
blood glucose, but elevations were observed in plasma
insulin levels in response to the cHF diet in ad libitum-fed
mice of both genotypes. However, the increase in plasma
insulin levels was less pronounced in AMPK2
/ mice,
closely reﬂecting the genotype-dependent differences in
body weight gain (Table 1). A similar pattern of changes in
insulin levels was also observed in fasted mice, in which
n-3 LC-PUFAs signiﬁcantly reduced insulin levels only in
wild-type animals (Table 1). As expected, plasma levels of
total as well as high molecular weight form of adiponectin,
an adipokine associated with increased insulin sensitivity
(35), were increased 1.4- and 1.2-fold, respectively, in
wild-type mice in response to n-3 LC-PUFA supplementa-
tion (Table 1 and supplementary Fig. 2, available in an
online appendix); however, no signiﬁcant increase of
plasma adiponectin by n-3 LC-PUFAs was observed in
AMPK2
/ mice.
In further experiments, hyperinsulinemic-euglycemic
clamps were performed to evaluate whole-body insulin
sensitivity. Under basal conditions, glucose turnover rate
(GTO; i.e., glucose uptake in peripheral tissues) was
similar in all groups of mice (supplementary Table 1).
Under insulin-stimulated conditions (Fig. 2A–F), the
amount of exogenous glucose required to maintain eugly-
cemia during the clamp, i.e., the glucose infusion rate
(GIR), was 1.3-fold lower in AMPK2
/ than in wild-
type mice fed the Chow diet (Fig. 2A). On the other hand,
GIR was decreased by the cHF diet to a similar level in
mice of both genotypes, manifesting diet-induced insulin
resistance. This was attributed to a decreased GTO and, in
particular, to an impaired suppression of hepatic glucose
production (HGP) by insulin, with HGP being 8.5-fold
higher in the cHF-fed compared with the Chow-fed wild-
type mice (Fig. 2C). In wild-type mice, cHFF diet feeding
increased GIR and GTO (1.9- and 1.2-fold increase,
respectively) as compared with cHF-fed mice, while HGP
was lowered to a similar level as in the Chow-fed mice.
These results document the protective effects of n-3 LC-
PUFAs from high-fat diet-induced insulin resistance in
wild-type mice, namely, at the level of HGP. In contrast,
none of these beneﬁcial effects of n-3 LC-PUFAs was
observed in AMPK2
/ mice, in which neither the GIR
(Fig. 2A) nor the GTO (Fig. 2B) differed between the
cHFF-fed and the cHF-fed mice, whereas the rate of HGP
was even higher in the cHFF-fed than in the cHF-fed
AMPK2
/ mice (Fig. 2C). Although whole-body glycol-
ysis was similar in all the groups (Fig. 2D), the rate of
whole-body glycogen synthesis, which reﬂects insulin sen-
sitivity of muscle glucose metabolism, was dependent on
both diet and genotype (Fig. 2E). In the Chow-fed mice,
the rate of whole-body glycogen synthesis tended to be
higher in wild-type mice than in AMPK2
/ mice. Only in
the former mice was it signiﬁcantly affected by dietary
treatment. Thus, in wild-type mice, glycogen synthesis was
TABLE 1
Metabolic and plasma parameters in wild-type and AMPK2
/ mice
Wild-type AMPK2
/
Metabolic parameters Chow cHF cHFF Chow cHF cHFF
Food consumption (kJ/g  day) 2.0 	 0.1 1.8 	 0.1 1.9 	 0.0 2.0 	 0.1 1.8 	 0.1 2.0 	 0.1
Initial body weight (g) 27.8 	 0.5 27.9 	 0.5 27.7 	 0.5 27.1 	 0.3 27.7 	 0.4 27.3 	 0.4
Body weight gain (g) 1.4 	 0.2 7.0 	 1.1* 2.8 	 0.7† 1.8 	 0.3 4.6 	 0.7*‡ 1.2 	 0.4†
Adiposity
Epididymal AT (g) 0.43 	 0.02 1.52 	 0.19* 1.12 	 0.14*† 0.37 	 0.03 1.19 	 0.16*‡ 0.64 	 0.07*†‡
Subcutaneous AT (g) 0.20 	 0.01 0.54 	 0.05* 0.42 	 0.04*† 0.17 	 0.01 0.34 	 0.03*‡ 0.23 	 0.01†‡
Epididymal adipocytes size (
m
2) ND 15,971 	 1,784 10,232 	 185† ND 13,298 	 1,632 8 593 	 896†
Subcutaneous adipocytes size (
m
2) 2,916 	 610 6,775 	 1,718* 7,311 	 1,308* 3,395 	 139 6,625 	 926* 5,432 	 648*
Plasma metabolites
Triglycerides (mmol/l) 1.17 	 0.08 1.23 	 0.11 0.62 	 0.07*† 1.04 	 0.06 1.22 	 0.08 0.73 	 0.06*†
NEFAs (mmol/l) 0.90 	 0.05 0.94 	 0.05 0.59 	 0.04*† 0.88 	 0.04 0.99 	 0.06 0.68 	 0.04*†
Cholesterol (mmol/l) 2.25 	 0.08 4.12 	 0.25* 3.10 	 0.20*† 2.10 	 0.06 3.94 	 0.18* 2.75 	 0.14*†
Glucose (mmol/l) 9.9 	 0.4 10.7 	 0.5 10.4 	 0.3 9.7 	 0.4 10.0 	 0.4 9.4 	 0.4
Plasma hormones
Insulin fed (ng/ml) 0.66 	 0.11 1.73 	 0.29* 1.47 	 0.28* 0.60 	 0.07 1.34 	 0.20* 0.95 	 0.12*
Insulin fasted (ng/ml) 0.13 	 0.01 0.39 	 0.06* 0.19 	 0.05† 0.16 	 0.02 0.22 	 0.03‡ 0.15 	 0.01
Total adiponectin (A.U.) 1.15 	 0.09 0.97 	 0.10 1.33 	 0.09† 0.82 	 0.09‡ 0.80 	 0.07 0.97 	 0.08‡
HMW: total adiponectin 0.38 	 0.02 0.36 	 0.02 0.44 	 0.02† 0.35 	 0.02 0.34 	 0.02 0.39 	 0.02
Data are means 	 SE of 27–30 mice for metabolic parameters and 13–15 mice for other measures. AMPK2
/ and wild-type mice were fed
either a Chow diet, cHF, or cHFF for nine weeks. Food consumption was measured weekly for nine weeks. Body weight gain (see
supplementary Fig. 1) and plasma parameters were assessed in ad libitum-fed mice after nine weeks. Plasma insulin levels were also assessed
in fasted mice after eight weeks. AT, adipose tissue; A.U., arbitary units; HMW, total adiponectin, ratio of high molecular weight to total
adiponectin (for levels of all molecular weight forms of adiponectin; ND, no data; see supplementary Fig. 2); *P  0.05 vs. genotype Chow;
†P  0.05 vs. genotype cHF; ‡P  0.05 vs. wild-type on respective diet.
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LC-PUFAs provided a partial protection from this decrease
(Fig. 2E). A similar pattern of changes in the glycogen
synthesis rate in response to n-3 LC-PUFAs was observed
when measured directly in the skeletal muscle (Fig. 2F).
Thus, in accordance with the previous study (26), the
results of clamp studies suggested impairment of insulin
sensitivity in response to whole-body ablation of AMPK2
in Chow-fed mice. However, AMPK2
/ mice seemed to
be partially protected against cHF-induced insulin resis-
tance, while AMPK2 was required for preservation of
insulin sensitivity in the skeletal muscle and especially in
the liver in response to n-3 LC-PUFA feeding.
Unmasking the role of AMPK2 in the lipid-lowering
effect of n-3 LC-PUFAs under hyperinsulinemic-eu-
glycemic conditions. In addition to the ad libitum-fed
mice (Table 1), plasma lipid levels were also measured in
fasted mice, as well as in mice subjected to hyperinsuline-
mic-euglycemic clamp (supplementary Table 2). In con-
trast to the ad libitum-fed state, cHFF diet did not affect
either triglyceride or NEFA levels under fasting condi-
tions. Under the hyperinsulinemic-euglycemic conditions,
both triglyceride and NEFA levels were lower in the
cHFF-fed than in the cHF-fed wild-type mice (1.6-fold
and 1.4-fold difference, respectively), but no such differ-
ence between the diets was observed in AMPK2
/ mice.
Cholesterol levels were consistently decreased by n-3
LC-PUFAs independently of both the metabolic state and
genotype (supplementary Table 2).
In ad libitum-fed mice of both genotypes, the hepatic
triglyceride content was increased twofold by cHF com-
pared with the Chow diet, while triglyceride accumulation
was increased only 1.3-fold by cHFF diet in both
genotypes, documenting a protection against hepatic tri-
glyceride accumulation by n-3 LC-PUFAs (Fig. 3A). Under
hyperinsulinemic-euglycemic conditions, n-3 LC-PUFAs
also protected livers of wild-type mice against the cHF-
induced accumulation of triglycerides. However, this ef-
fect was absent in AMPK2
/ mice (Fig. 3B). Moreover,
a strong correlation was found between plasma NEFA
levels and hepatic triglyceride content assessed under the
clamp conditions in the cHFF-fed AMPK2
/ mice
(R
2  0.43, P  0.05) but not in wild-type mice (R
2  0.08,
P  0.40).
Dietary n-3 LC-PUFAs increase 5-aminoimidazole-4-
carboxamide-1--D-ribofuranoside–stimulated fatty
acid oxidation and insulin-stimulated lipogenesis in
cultured hepatocytes from wild-type but not from
AMPK2
/ mice. We sought to determine whether the
differential effect of n-3 LC-PUFAs on accumulation of
liver triglycerides in wild-type and AMPK2
/ mice under
the clamp conditions could be explained by hepatic lipid
metabolism. In cultured hepatocytes isolated from mice
following the different dietary treatments, activities of
both fatty acid oxidation and de novo fatty acid synthesis
were evaluated. The stimulatory effects of 5-aminoimida-
zole-4-carboxamide-1--D-ribofuranoside (AICAR), an
AMPK activator, and insulin on fatty acid oxidation and
synthesis are shown in Fig. 4A and B, respectively (for
corresponding basal metabolic activities, see supplemen-
tary Table 3, available in an online appendix). In hepato-
cytes from both Chow and cHF diet-fed mice, the absence
of AMPK2 was associated with a trend for lower AICAR-
stimulated fatty acid oxidation. Although hepatocytes
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FIG. 2. Insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp. GIR (A), GTO (B), HGP (C), whole-body glycolysis (GL-WB; D),
whole-body glycogen synthesis (GS-WB; E); and glycogen synthesis in quadriceps muscle (GS-QM; F) were measured in wild-type and AMPK2
/
mice fed either a Chow diet, cHF, or cHFF for 9 weeks. The data are the means  SE (n  5–8). *P < 0.05 versus genotype Chow; †P < 0.05
versus genotype cHF; ‡P < 0.05 versus wild-type on respective diet.
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AICAR irrespective of the genotype, cHFF feeding nor-
malized this defect in wild-type but not in AMPK2
/
hepatocytes (Fig. 5A), suggesting AMPK-dependent induc-
tion of capacity for fatty acid oxidation by n-3 LC-PUFAs
in the liver. The stimulatory effect of insulin on de novo
fatty acid synthesis was reduced in hepatocytes from
cHF-fed wild-type mice, whereas it was retained in the
hepatocytes from cHF-fed AMPK2
/ mice (Fig. 4B).
cHFF feeding tended to restore the stimulatory effect of
insulin only in wild-type hepatocytes (Fig. 4B).
To further characterize hepatic effects of differential
dietary treatment, the expression of selected genes was
quantiﬁed in total RNA isolated from the livers of mice
subjected to hyperinsulinemic-euglycemic clamp (Fig. 4C
and D). Feeding cHF diet suppressed expression of lipo-
genic genes stearoyl-CoA desaturase (SCD-1) and
SREBP-1c in all groups (except for SREBP-1c in
AMPK2
/ mice). This suppression was partially coun-
teracted by cHFF diet in wild-type but not AMPK2
/
mice (Fig. 4C and D). Together with the de novo fatty acid
synthesis data, these results further support the AMPK2-
dependent improvement of liver insulin sensitivity by n-3
LC-PUFAs.
Changes in hepatic diacylglycerol levels are associ-
ated with insulin-sensitizing effects of n-3 LC-PUFAs.
To identify factors predisposing animals to insulin resis-
tance in an AMPK2-dependent manner, a detailed analy-
sis of hepatic lipids in ad libitum-fed mice was performed.
No major genotype-dependent differences in the contents
of either ceramides or phospholipids were observed (sup-
plementary Table 4). In contrast, hepatic content of dia-
cylglycerols was affected in a genotype- and diet-
dependent manner (Fig. 5A). Wild-type mice fed the
cHFF diet had lower diacylglycerol content than geno-
type-matched cHF diet-fed mice, while this effect of the
cHFF diet was not observed in AMPK2
/ mice. More-
over, the analysis of fatty acid composition of the diacyl-
glycerol fraction in the liver revealed that wild-type as well
as AMPK2
/ mice fed cHF diet were characterized by
marked increase in the level of PUFA but not monounsat-
urated or saturated fatty acids (Fig. 5B, C, and D and
supplementary Table 4). The increase in the PUFA content
tended to be smaller in the wild-type compared with
AMPK2
/ mice (1.7-fold and 2.2-fold, respectively).
Administration of n-3 LC-PUFAs completely prevented
accumulation of hepatic polyunsaturated diacylglycerols
in wild-type mice, whereas their level in the AMPK2
/
animals, although decreased, was still signiﬁcantly higher
compared with genotype-matched Chow-fed mice (Fig.
5B). Regarding polyunsaturated diacylglycerols, -linole-
nic acid (18:3n-3) appeared to be by far the most differen-
tially regulated PUFA in the diacylglycerol fraction in the
two genotypes (supplementary Table 4). In addition,
cHFF diet markedly reduced hepatic content of mono-
unsaturated diacylglycerols in wild-type but not in knock-
out animals (Fig. 5C). Hepatic diacylglycerol levels and
their fatty acid composition were also analyzed in mice
subjected to hyperinsulinemic-euglycemic clamp (supple-
mentary Table 5 and supplementary Fig. 3). No signiﬁcant
differences among the groups were observed in total
diacylglycerols content or in their saturated or monoun-
saturated fatty acid fractions (supplementary Fig. 3).
DISCUSSION
Previous animal studies demonstrated that n-3 LC-PUFAs
could counteract the development of both hepatic steato-
sis (8,18,36,37) and hepatic insulin resistance (8,9,16),
while suppressing lipogenesis and augmenting lipid catab-
olism in the liver (8,13,19,21). Using mice with a whole-
body deletion of AMPK2 and high-fat feeding, we show
for the ﬁrst time that AMPK2 is required for the effect of
n-3 LC-PUFAs to preserve whole-body, muscle, and espe-
cially hepatic insulin sensitivity, as well as to suppress
hepatic and plasma triglycerides as well as NEFA levels
under hyperinsulinemic-euglycemic clamp conditions. In
contrast, AMPK2 was not required for protection by n-3
LC-PUFAs from hepatic lipid accumulation and dyslipide-
mia in ad libitum-fed mice.
In addition to AMPK2, PPAR was previously identi-
ﬁed as an important determinant of n-3 LC-PUFA’s effect
on lipid metabolism, especially short-term modulation of
hepatic gene expression (14) and insulin sensitivity (16).
Thus, the reduction in hepatic triglyceride concentrations
by ﬁsh oil feeding did not rescue insulin action in PPAR-
null mice, while hepatic diacylglycerol concentrations
were decreased by ﬁsh oil in a PPAR-dependent manner
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sensitivity (16). It is generally accepted that 1) diacylglyc-
erols rather than triglycerides or ceramides mediate he-
patic insulin resistance in mice fed a high-fat diet
(19,38,39), 2) diacylglycerol-induced insulin resistance de-
pends on activation of protein kinase C, and 3) that
polyunsaturated diacylglycerols in particular are better
protein kinase C activators than saturated diacylglycerol
species [reviewed in refs (38,39)]. Also our results showed
that cHF diet-induced insulin resistance was associated
primarily with the accumulation of PUFA in hepatic dia-
cylglycerols and that n-3 LC-PUFA completely prevented
cHF diet-induced increase in PUFA diacylglycerols in
wild-type mice, whereas in AMPK2
/ animals, the con-
tent of these lipids was still signiﬁcantly higher compared
with the control. Moreover, it was only in ad libitum-fed
mice but not in mice subjected to hyperinsulinemic-
euglycemic clamps that the levels of hepatic diacylglycer-
ols and their fatty acid compositions were associated with
hepatic insulin sensitivity. It is possible that under clamp
conditions AMPK2-dependent effects of n-3 LC-PUFAs on
liver diacylglycerols were masked by metabolic changes
occurring during a 3-h infusion of insulin and glucose.
The failure of n-3 LC-PUFAs to decrease hepatic lipids in
AMPK2
/ mice under clamp conditions could be due to
primary alterations in metabolic ﬂuxes in the liver, reﬂect-
ing 1) increased de novo fatty acid synthesis, 2) decreased
secretion of VLDL triglycerides, or 3) reduced fatty acid
oxidation. De novo fatty acid synthesis was not the
responsible factor, because hepatocytes of the n-3 LC-
PUFA-fed AMPK2
/ mice showed decreased insulin-
stimulated de novo fatty acid synthesis and reduced
expression of SREBP-1c and SCD-1, as compared with
hepatocytes isolated from n-3 LC-PUFA-fed wild-type
mice, reﬂecting probably low insulin sensitivity of the liver
in AMPK2
/ mice. Moreover, AICAR-stimulated fatty
acid oxidation in hepatocytes from n-3 LC-PUFA-fed
AMPK2
/ mice was markedly reduced as compared
with those from wild-type mice, suggesting decreased
hepatic capacity for fatty acid oxidation in the absence of
AMPK2, which could contribute to enhanced lipid accu-
mulation. Therefore, these experiments supported a major
role of hepatic AMPK2 in the regulation of both insulin
sensitivity and lipid metabolism by n-3 LC-PUFAs. How-
ever, the differential modulation of lipid accumulation by
n-3 LC-PUFAs in the livers of wild-type and AMPK2
/
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the AMPK2-dependent effects of n-3 LC-PUFAs in other
tissues, resulting in a relatively high hepatic uptake of
circulating NEFA in AMPK2
/ mice. This is supported
by persistently elevated plasma levels of NEFA in
AMPK2
/ mice, as well as by a signiﬁcant correlation
between plasma NEFA levels and hepatic triglyceride
content observed under clamp conditions in AMPK2
/
but not wild-type mice fed n-3 LC-PUFA-containing diet.
Moreover, it has been shown in humans with nonalcoholic
fatty liver disease that most of hepatic triglycerides arise
from circulating NEFA (40). That plasma NEFA levels
under clamp conditions were reduced only in wild-type
but not in AMPK2
/ mice fed n-3 LC-PUFAs may reﬂect
a role of AMPK2 in muscle lipid uptake mediated by
lipoprotein lipase (41), as well as the antilipolytic effect of
AMPK in adipose tissue, documented for AMPK1 (42). In
any case, decreased fatty acid oxidation in situ in the liver
and, possibly even more importantly, abundant supply of
circulating NEFA could be responsible for the lack of the
antisteatotic effect of n-3 LC-PUFAs in AMPK2
/ mice
under clamp conditions (Fig. 6).
Previous studies reported contradictory results, show-
ing either 1) activation of AMPK in rat liver (22) and
murine adipose tissue (24) or 2) no changes in AMPK
activity in the liver, skeletal muscle, and heart of mice (43)
in response to dietary n-3 LC-PUFAs. These discrepancies
could be related to differences in dietary n-3 LC-PUFA
intake, nutritional state of animals, and other parameters.
In accordance with the involvement of AMPK2 in various
effects of n-3 LC-PUFAs, our results document activation
of AMPK2 (but not AMPK1) in the liver of mice by
long-term n-3 LC-PUFA treatment, in the absence of sig-
niﬁcant changes in either the AMP to ATP ratio assessed in
whole liver extracts [not shown and ref (44)] or the
phosphorylation status of LKB1, an upstream kinase for
AMPK [not shown and ref (45)]. In addition, no effect on
AMPK activity in either cultured hepatocytes (21) or
embryonic kidney cells (not shown) of n-3 LC-PUFAs
added to the cell culture medium could be detected.
Therefore, the activation of AMPK2 by n-3 LC-PUFAs
probably does not depend on a direct interaction between
n-3 LC-PUFAs and AMPK. On the other hand, induction of
adiponectin by n-3 LC-PUFAs [results of this study and
refs (46,47)] could be involved, because adiponectin acti-
vates AMPK in both the liver and skeletal muscle (35).
Adiponectin is also required for the activation of AMPK
upon administration of PPAR agonists thiazolidinedio-
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hepatic insulin sensitivity and reduced responsiveness to
these compounds (48). Thus, absence of AMPK2 may
blunt adiponectin-mediated effects of n-3 LC-PUFAs. In
accordance with the previous study (49), plasma adi-
ponectin levels tended to be reduced in AMPK2
/ mice.
Moreover, the induction of adiponectin by n-3 LC-PUFAs
in AMPK2
/ mice was compromised (Table 1 and
supplementary Figure 2).
AMPK1 and AMPK2 contribute equally to total AMPK
activity in the liver (50). In mice with liver-speciﬁc ablation
of AMPK2 (27), hepatic AMPK2 was essential for sup-
pressing hepatic glucose production and maintaining fast-
ing blood glucose levels; however, the absence of AMPK2
did not affect inhibitory action of insulin on hepatic
glucose production. In our study, although fasting blood
glucose levels were unaltered by whole-body ablation of
AMPK2, the beneﬁcial effect of dietary n-3 LC-PUFAs on
hepatic insulin sensitivity was clearly AMPK2-dependent.
Differential regulation of glucose homeostasis in the above
transgenic models likely reﬂects the complexity of whole-
body (26) versus liver-speciﬁc (27) deletion of AMPK2. In
contrast to the previous report, showing induction of
adiposity and adipocyte hypertrophy in AMPK2
/ mice
fed a lard-based high-fat diet (49), our study documented a
relatively low weight gain, low adiposity, and smaller fat
cells in AMPK2
/ mice fed a corn-oil based high-fat diet.
This discrepancy could be related to the differences in the
composition of experimental high-fat diets; however, our
results are consistent with the elevated sympathetic tonus
of AMPK2
/ mice (26), which may stimulate energy
dissipation in these animals. In any case, lower body
weight of cHF-fed AMPK2
/ mice as compared with
their wild-type counterparts could be related to better
insulin sensitivity of the former mice, as suggested by the
differences in insulinemia, results of hyperinsulinemic-
euglycemic clamp, stimulatory effect of insulin on lipogen-
esis, and expression of lipogenic genes in the liver.
In conclusion, the preservation of hepatic insulin sensi-
tivity by n-3 LC-PUFAs in mice fed a high-fat diet depends
on AMPK2. The accumulation of diacylglycerols, which is
regulated in an AMPK2-dependent manner, could con-
tribute to the modulation of hepatic insulin sensitivity in
response to dietary n-3 LC-PUFAs. On the other hand, the
AMPK2-dependent acute changes in lipid metabolism
and hepatic triglyceride accumulation, which are un-
masked under insulin-stimulated conditions such as dur-
ing hyperinsulinemic-euglycemic clamp, largely reﬂect the
extrahepatic action of n-3 LC-PUFAs. Our results are
relevant for the development of novel strategies for pre-
vention and treatment of the metabolic syndrome.
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